Evidence map›Paper›PMID 36884035›Full record

ReviewThe Cochrane database of systematic reviews2023

Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer.

Sunghyun Kim, Jee Hyun Kong, YoHan Lee, Jun Young Lee, Tae Wook Kang, Tae Hoon Kong, Myung Ha Kim, Sei Hwan You

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Cochrane database of systematic reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Sunghyun Kim *Department of Radation Oncology, Yonsei University Wonju College of Medicine, Wonju, Korea, South.
Jee Hyun Kong *Department of Hematology-Oncology, Division of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea, South.
YoHan LeeDepartment of Radation Oncology, Yonsei University Wonju College of Medicine, Wonju, Korea, South.
Jun Young LeeCenter of Evidence Based Medicine, Institute of Convergence Science, Yonsei University, Seoul, Korea, South.
Tae Wook KangDepartment of Urology, Yonsei University Wonju College of Medicine, Wonju, Korea, South.
Tae Hoon KongDepartment of Otorhinolaryngology Head and neck surgery, Yonsei University Wonju College of Medicine, Wonju, Korea, South.
Myung Ha KimYonsei Wonju Medical Library, Yonsei University Wonju College of Medicine, Wonju, Korea, South.
Sei Hwan YouDepartment of Radation Oncology, Yonsei University Wonju College of Medicine, Wonju, Korea, South.
Yonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatments for clinically localized prostate cancer include radical prostatectomy, external beam radiation therapy, brachytherapy, active surveillance, hormonal therapy, and watchful waiting. For external beam radiation therapy, oncological outcomes may be expected to improve as the dose of radiotherapy (RT) increases. However, radiation-mediated side effects on surrounding critical organs may also increase.

objectivesTo assess the effects of dose-escalated RT in comparison with conventional dose RT for curative treatment of clinically localized and locally advanced prostate cancer. SEARCH

methodsWe performed a comprehensive search using multiple databases including trial registries and other sources of grey literature, up until 20 July 2022. We applied no restrictions on publication language or status. SELECTION CRITERIA: We included parallel-arm randomized controlled trials (RCTs) of definitive RT in men with clinically localized and locally advanced prostate adenocarcinoma. RT was dose-escalated RT (equivalent dose in 2 Gy [EQD DATA COLLECTION AND ANALYSIS: Two review authors independently abstracted data from the included studies. We performed statistical analyses by using a random-effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. We used GRADE guidance to rate the certainty of the evidence of RCTs. MAIN

resultsWe included nine studies with 5437 men in an analysis comparing dose-escalated RT versus conventional dose RT for the treatment of prostate cancer. The mean participant age ranged from 67 to 71 years. Almost all men had localized prostate cancer (cT1-3N0M0). Primary outcomes Dose-escalated RT probably results in little to no difference in time to death from prostate cancer (hazard ratio [HR] 0.83, 95% CI 0.66 to 1.04; I AUTHORS'

conclusionsCompared to conventional dose RT, dose-escalated RT probably results in little to no difference in time to death from prostate cancer, time to death from any cause, time to distant metastasis, and RT toxicities (except overall late GI toxicity). While dose-escalated RT may increase overall late GI toxicity, it may result, or probably results, in little to no difference in physical and mental quality of life, respectively.

Indexed as

Prostatic NeoplasmsAgedHumansMaleProstatectomySystematic Reviews as Topic

Identifiers

PMID36884035
PMCPMC9994460
OpenAlexW4323534282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.